Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenThe CD44+/CD24- phenotype is enriched in basal-like breast tumorsNottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancerAn intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situAPRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerPEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cellsPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerLoss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancersUnderstanding and treating triple-negative breast cancerAfrican ancestry and higher prevalence of triple-negative breast cancer: findings from an international studyA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesNF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivationAssociation of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancerFragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancerIL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary glandEstablishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression dataAn early peak of relapse after surgery for breast cancerBasal cytokeratins and their relationship to the cellular origin and functional classification of breast cancerGenome-scale identification of membrane-associated human mRNAs.Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerBreast cancer intrinsic subtype classification, clinical use and future trendsMiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerBiomarkers in triple negative breast cancer: A reviewThe fate of chemoresistance in triple negative breast cancer (TNBC)Targeted Therapies in Triple-Negative Breast CancerTargeting triple-negative breast cancer: optimising therapeutic outcomesMicroRNAs and triple negative breast cancerGenomic approaches in breast cancer researchQuantification of HER family receptors in breast cancerNear Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light RegimenVandetanib as a potential new treatment for estrogen receptor-negative breast cancers.A perspective on anti-EGFR therapies targeting triple-negative breast cancerBreast cancer molecular subtypes: from TNBC to QNBCTriple-negative breast cancer: is there a treatment on the horizon?FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceAppraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breastEfficacy of neoadjuvant Cisplatin in triple-negative breast cancer
P2860
Q21092375-887764C6-89C7-4C49-9226-93C09B11CC70Q21092906-87619006-55C9-45AF-9EFB-1107D93CA7CCQ21261291-4552C81B-C7FD-48D6-AA22-2FE1825DF3A3Q21560948-FDD1DF35-ACA7-4C4B-A1CF-D5EBFAA6EDA2Q22000769-8AC762E0-0731-4FE3-8A5F-D125EFA945E8Q24304176-1CA07B33-FD4D-4171-856F-FC951FD7BB47Q24323230-33E644CC-5056-4900-9944-A3B02024FE08Q24563045-AE095B68-8728-4A2F-A994-7CAA39BDDCC8Q24620397-AE812FDA-838D-44D1-A204-5132513BCB16Q24620957-F8B91D04-56C3-477A-A1C0-5D3EDFDCF5B1Q24632274-D4C4F0A6-FBED-458F-9B70-9AAE9CF79FF3Q24647928-1EC10588-1113-41F2-8A8C-3FD598AD170DQ24653076-2DDA118A-A08A-4A63-A775-8D988B044BD2Q24653339-59132D63-9101-43BA-B8FC-68831382564CQ24654216-F78FF6A5-99FA-4773-96E0-3D4FDF69C61FQ24669531-8C8358C6-7875-45E5-AF22-F103129391A2Q24684071-08B5ED48-FEA7-495A-A4A2-8C2B3F4F033BQ24796254-B08DDE14-409D-414A-8B5F-C8F7B8597A7CQ24810751-478B554A-F347-4BEC-B491-B952A390946AQ25256725-5D963CCC-825E-4428-A6AA-D0EEF252A7DEQ25257542-94004E8F-7EDD-4965-8C7F-F00EB6A846A1Q26743510-41878BB9-7AE3-4F30-8752-5AD994887023Q26752846-A7DA250B-8D7B-49E1-A950-4A9B401C6134Q26773761-C9D8604C-CB75-487C-8438-0B98B2CDF5C3Q26775086-57BA0748-DC79-4B82-B01E-2A62B402AD94Q26775094-E7DD1BC4-B429-4B54-AD2D-DCF748F9B427Q26775232-DD39606E-1BC3-4E45-89EE-38EC0AB29D55Q26777736-987487A4-87B2-4FC4-82E3-54C8AE371D19Q26850892-27E91291-4585-4393-9860-A3116E832358Q26862716-5F1DA2E4-A854-425A-AC14-78A2E4A2F52EQ26865893-578E12B4-EEE4-4CCF-8BD7-AA67DB8E3332Q27015506-47376EED-1935-4F9B-914D-A75739BFA9BDQ27320934-2AADE4F2-DB5D-42AD-B870-A6D748667191Q27853297-730BFD70-6AB6-4C83-B97E-EE9D4AD315B3Q28069867-DBE44D31-D4BF-4C59-BC90-EABE714A7848Q28076805-1FAD349D-08AD-463A-AC6F-C4048D5AE1E7Q28077243-D60108DD-40B7-44AA-B7E4-4F615DBA814AQ28077347-8DB169D6-24EF-4F58-B5B0-47E70289EA51Q28083103-FA6D0EF1-8DA4-4EB8-A3FF-0E65F4A5A17DQ28372484-66C5E8B1-9B74-404F-8592-30EE9E73FFDA
P2860
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@en
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@nl
type
label
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@en
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@nl
prefLabel
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@en
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@nl
P2093
P50
P1476
Immunohistochemical and clinic ...... of invasive breast carcinoma.
@en
P2093
Allen M Gown
C Blake Gilks
Chad Livasy
Dave Cowan
Forrest D Hsu
Gamze Karaca
Joseph Ragaz
Kristin Jensen
Lynn Dressler
Maggie Cheang
P304
P356
10.1158/1078-0432.CCR-04-0220
P407
P577
2004-08-01T00:00:00Z